Non-Alcoholic Fatty Liver Disease Is Associated with an Increased Incidence of Atrial Fibrillation in Patients with Type 2 Diabetes

PLoS ONE

Volumn 8, Issue 2, 2013, Pages

  Targher, Giovanni ^a   Valbusa, Filippo ^b   Bonapace, Stefano ^b   Bertolini, Lorenzo ^b   Zenari, Luciano ^b   Rodella, Stefano ^b   Zoppini, Giacomo ^a   Mantovani, William ^c,d   Barbieri, Enrico ^b   Byrne, Christopher D ^e,f  

^a University and Azienda Ospedaliera Universitaria Integrata of Verona   (Italy)

^b SACRO CUORE DON CALABRIA HOSPITAL   (Italy)

^c UNIVERSITY OF VERONA   (Italy)

^d Public Health Department   (Italy)

^e UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^f UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; GAMMA GLUTAMYLTRANSFERASE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; ORAL ANTIDIABETIC AGENT; TRIACYLGLYCEROL;

ADULT; AGE; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CARDIOVASCULAR RISK; CAROTID ARTERY OBSTRUCTION; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE DURATION; DRUG MONITORING; ECHOGRAPHY; FEMALE; FOLLOW UP; FRAMINGHAM RISK SCORE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; INCIDENCE; INCIDENTAL FINDING; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; PR INTERVAL; PREDICTIVE VALUE; PROSPECTIVE STUDY; PULSE PRESSURE; SENSITIVITY ANALYSIS; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL;

AGED; ATRIAL FIBRILLATION; DIABETES MELLITUS, TYPE 2; FATTY LIVER; FEMALE; HUMANS; INCIDENCE; INCIDENTAL FINDINGS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES;

EID: 84874317741     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0057183     Document Type: Article

References (36)

1. Ratziu V, Bellentani S, Cortez-Pinto H, Day C, Marchesini G, (2010) A position statement on NAFLD/NASH based on the EASL 2009 special conference. J Hepatol 53: 372-384.
2. Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, et al. (2012) The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 55: 2005-2023.
3. Targher G, Day CP, Bonora E, (2010) Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med 363: 1341-1350.
4. Bhatia LS, Curzen NP, Calder PC, Byrne CD, (2012) Non-alcoholic fatty liver disease: a new and important cardiovascular risk factor? Eur Heart J 33: 1190-1200.
5. Goland S, Shimoni S, Zornitzki T, Knobler H, Azoulai O, et al. (2006) Cardiac abnormalities as a new manifestation of nonalcoholic fatty liver disease: echocardiographic and tissue Doppler imaging assessment. J Clin Gastroenterol 40: 949-955.
6. Bonapace S, Perseghin G, Molon G, Canali G, Bertolini L, et al. (2012) Nonalcoholic fatty liver disease is associated with left ventricular diastolic dysfunction in patients with type 2 diabetes. Diabetes Care 35: 389-395.
7. Hallsworth K, Hollingsworth KG, Thoma C, Jakovljevic D, Macgowan GA, et al. (2012) Cardiac structure and function are altered in adults with non-alcoholic fatty liver disease. J Hepatol doi: 10.1016/j.jhep.2012.11.015 [Epub ahead of print].
8. Dhingra R, Gona P, Wang TJ, Fox CS, D'Agostino RB, et al. (2010) Serum gamma-glutamyl-transferase and risk of heart failure in the community. Arterioscler Thromb Vasc Biol 30: 1855-1860.
9. Wannamethee SG, Whincup PH, Shaper AG, Lennon L, Sattar N, (2012) Gamma-glutamyltransferase, hepatic enzymes and risk of incident heart failure in older men. Arterioscler Thromb Vasc Biol 32: 830-835.
10. Lip GY, Tse HF, Lane DA, (2012) Atrial fibrillation. Lancet 379: 648-661.
11. Miyasaka Y, Barnes ME, Gersh BJ, Cha SS, Bailey KR, et al. (2006) Secular trends in incidence of atrial fibrillation in Olmsted Country, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation 114: 119-125.
12. Benjamin EJ, Levy D, Vaziri SM, D'Agostino RB, Belanger AJ, et al. (1994) Independent risk factors for atrial fibrillation in a population-based cohort: the Framingham Heart Study. JAMA 271: 840-844.
13. Psaty BM, Manolio TA, Kuller LH, Kronmal LA, Cushman M, et al. (1997) Incidence of and risk factors for atrial fibrillation in older adults. Circulation 96: 2455-2461.
14. Nichols GA, Reinier K, Chugh SS, (2009) Independent contribution of diabetes to increased prevalence and incidence of atrial fibrillation. Diabetes Care 32: 1851-1856.
15. Jabre P, Roger VL, Murad MH, Chamberlain AM, Prokop L, et al. (2011) Mortality associated with atrial fibrillation in patients with myocardial infarction: a systematic review and meta-analysis. Circulation 123: 1587-1593.
16. Sinner MF, Wang N, Fox CS, Fontes JD, Rienstra M, et al. (2013) Relation of circulating liver transaminase concentrations to risk of new-onset atrial fibrillation. Am J Cardiol 111: 219-224.
17. Vanezis AP, Bhopal R, (2008) Validity of electrocardiographic classification of left ventricular hypertrophy across adult ethnic groups with echocardiography as a standard. J Electrocardiol 41: 404-412.
18. American Diabetes Association, (2012) Standards of medical care in diabetes- 2012. Diabetes Care 35(suppl 1): S11-S63.
19. Mehta SR, Thomas EL, Bell JD, Johnston DG, Taylor-Robinson SD, (2008) Non-invasive means of measuring hepatic fat content. World J Gastroenterol 14: 3476-3483.
20. Schnabel RB, Sullivan LM, Levy D, Pencina MJ, Massaro JM, et al. (2009) Development of a risk score for atrial fibrillation (Framingham Heart Study): a community-based cohort study. Lancet 373: 739-745.
21. Makar GA, Weiner MG, Kimmel SE, Bennet D, Burke A, et al. (2008) Incidence and prevalence of abnormal liver associated enzymes in patients with atrial fibrillation in a routine clinical care population. Pharmacoepidemiol Drug Saf 17: 43-51.
22. Tsang TS, Gersh BJ, Appleton CP, Tajik AJ, Barnes ME, et al. (2002) Left ventricular diastolic dysfunction as a predictor of the first diagnosed non-valvular atrial fibrillation in 840 elderly men and women. J Am Coll Cardiol 40: 1636-1644.
23. Darbar D, Jahangir A, Hammill SC, Gersh BJ, (2002) P wave signal-averaged electrocardiography to identify risk for atrial fibrillation. Pacing Clin Electrophysiol 25: 1447-1453.
24. Rosenberg MA, Gottdiener JS, Heckbert SR, Mukamal KJ, (2012) Echocardiographic diastolic parameters and risk of atrial fibrillation: the Cardiovascular Health Study. Eur Heart J 33: 904-912.
25. Chamberlain AM, Agarwal SK, Folsom AR, Soliman EZ, Chambless LE, et al. (2011) A clinical risk score for atrial fibrillation in a biracial prospective cohort (from the Atherosclerosis Risk in Communities [ARIC] study). Am J Cardiol 107: 85-91.
26. Rijzewijk LJ, van der Meer RW, Smit JW, Diamant M, Bax JJ, et al. (2008) Myocardial steatosis is an independent predictor of diastolic dysfunction in type 2 diabetes mellitus. J Am Coll Cardiol 52: 1793-1799.
27. Ng AC, Delgado V, Bertini M, van der Meer RW, Rijzewijk LJ, et al. (2010) Myocardial steatosis and biventricular strain and strain rate imaging in patients with type 2 diabetes mellitus. Circulation 122: 2538-2544.
28. Fox CS, Gona P, Hoffmann U, Porter SA, Salton CJ, et al. (2009) Pericardial fat, intrathoracic fat, and measures of left ventricular structure and function: the Framingham Heart Study. Circulation 119: 1586-1591.
29. Thanassoulis G, Massaro JM, O'Donnell CJ, Hoffmann U, Levy D, et al. (2010) Pericardial fat is associated with prevalent atrial fibrillation: the Framingham Heart Study. Circ Arrhythm Electrophysiol 3: 345-350.
30. Shin SY, Yong HS, Lim HE, Na JO, Choi CU, et al. (2011) Total and interatrial epicardial adipose tissues are independently associated with left atrial remodeling in patients with atrial fibrillation. J Cardiovasc Electrophysiol 22: 647-655.
31. Lin YK, Chen YC, Chen JH, Chen SA, Chen YJ, (2012) Adipocytes modulate the electrophysiology of atrial myocytes: implications in obesity-induced atrial fibrillation. Basic Res Cardiol 107: 293.
32. Targher G, Chonchol M, Miele L, Zoppini G, Pichiri I, et al. (2009) Non-alcoholic fatty liver disease as a contributor to hypercoagulation and thrombophilia in the metabolic syndrome. Semin Thromb Hemost 35: 277-287.
33. Chung MK, Martin DO, Sprecher D, Wazni O, Kanderian A, et al. (2001) C-reactive protein elevation in patients with atrial arrhythmias. Inflammatory mechanisms and persistence of atrial fibrillation. Circulation 104: 2886-2891.
34. Liu T, Li G, Li L, Korantzopoulos P, (2007) Association between C-reactive protein and recurrence of atrial fibrillation after successful electrical cardioversion: a meta-analysis. J Am Coll Cardiol 49: 1642-1648.
35. Schnabel RB, Larson MG, Yamamoto JF, Sullivan LM, Pencina MJ, et al. (2010) Relations of biomarkers of distinct pathophysiological pathways and atrial fibrillation incidence in the community. Circulation 121: 200-207.
36. Conen D, Ridker PM, Everett BM, Tedrow UB, Rose L, et al. (2010) A multimarker approach to assess the influence of inflammation on the incidence of atrial fibrillation in women. Eur Heart J 31: 1730-1736.